Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5101 AL 5115

Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights

Mehta DC, Short JL, Hilmer SN, Nicolazzo JA.

Pharm Res. 2015 Mar;32(3):819-39. doi: 10.1007/s11095-014-1522-0. Epub 2014 Oct 16.

Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease

Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM.

J Pharmacol Exp Ther. 2015 Jan;352(1):110-8. doi: 10.1124/jpet.114.219352. Epub 2014 Oct 15.

Stem cell treatment for Alzheimer's disease

Li M, Guo K, Ikehara S.

Int J Mol Sci. 2014 Oct 23;15(10):19226-38. doi: 10.3390/ijms151019226.

Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease

Ahmad MZ, Ahmad J, Amin S, Rahman M, Anwar M, Mallick N, Ahmad FJ, Rahman Z, Kamal MA, Akhter S.

CNS Neurol Disord Drug Targets. 2014;13(8):1315-24. doi: 10.2174/1871527313666141023100618.

[Economic impact of Alzheimer's Disease in Brazil: is it possible to improve care and minimize costs?]

Gutierrez BA, Silva HS, Guimarães C, Campino AC.

Cien Saude Colet. 2014 Nov;19(11):4479-86. doi: 10.1590/1413-812320141911.03562013.

FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease

Paroni G, Seripa D, Fontana A, D'Onofrio G, Gravina C, Urbano M, Cascavilla L, Pellegrini F, Greco A, Pilotto A.

Clin Interv Aging. 2014 Oct 21;9:1783-91. doi: 10.2147/CIA.S64758. eCollection 2014.

Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease

Han HJ, Kwon JC, Kim JE, Kim SG, Park JM, Park KW, Park KC, Park KH, Moon SY, Seo SW, Choi SH, Cho SJ.

Eur Neurol. 2015;73(1-2):23-8. doi: 10.1159/000366198. Epub 2014 Nov 1.

Structure and mechanism of action of tau aggregation inhibitors

Cisek K, Cooper GL, Huseby CJ, Kuret J.

Curr Alzheimer Res. 2014;11(10):918-27. doi: 10.2174/1567205011666141107150331.

Epigenetic nutraceutical diets in Alzheimer's disease

Davinelli S, Calabrese V, Zella D, Scapagnini G.

J Nutr Health Aging. 2014 Nov;18(9):800-5. doi: 10.1007/s12603-014-0552-y.

Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease

Cagnin A, Cester A, Costa B, Ermani M, Gabelli C, Gambina G; SWITCH study working group.

Neurol Sci. 2015 Mar;36(3):457-63. doi: 10.1007/s10072-014-2002-3. Epub 2014 Nov 14.

The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer's Disease

Nagase H, Nakayama K.

Curr Drug Discov Technol. 2014;11(4):243-58. doi: 10.2174/1570163811666141121101358.

What are the Benefits of Exercise for Alzheimer's Disease? A Systematic Review of the Past 10 Years

Hernández SS, Sandreschi PF, da Silva FC, Arancibia BA, da Silva R, Gutierres PJ, Andrade A.

J Aging Phys Act. 2015 Oct;23(4):659-68. doi: 10.1123/japa.2014-0180. Epub 2014 Nov 21.

Medical genetics-based drug repurposing for Alzheimer's disease

Zhang XZ, Quan Y, Tang GY.

Brain Res Bull. 2015 Jan;110:26-9. doi: 10.1016/j.brainresbull.2014.11.003. Epub 2014 Nov 22.

Improving the predictive value of interventional animal models data

Zeiss CJ.

Drug Discov Today. 2015 Apr;20(4):475-82. doi: 10.1016/j.drudis.2014.10.015. Epub 2014 Nov 4.

Amyloid beta peptide immunotherapy in Alzheimer disease

Delrieu J, Ousset PJ, Voisin T, Vellas B.

Rev Neurol (Paris). 2014 Dec;170(12):739-48. doi: 10.1016/j.neurol.2014.10.003. Epub 2014 Nov 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias